Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

NCT02088645 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT02088645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02088645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 30, 2015
Completion date
April 30, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumor gep grade 1-3, neuroendocrine tumor of the lung grade 1 and 2, neuroendocrine tumor of the thymus grade 1 and 2, thyroid cancer, medullary